Published in J Clin Endocrinol Metab on June 01, 1998
Insulin induces the release of vasodilator compounds from platelets by a nitric oxide-G kinase-VAMP-3-dependent pathway. J Exp Med (2004) 0.97
Insulin rapidly stimulates L-arginine transport in human aortic endothelial cells via Akt. Biochem Biophys Res Commun (2011) 0.80
Insulin resistance as a contributor to myocardial ischaemia independent of obstructive coronary atheroma: a role for insulin sensitisation? Heart (2004) 0.78
Influence of physiological and supraphysiological hyperinsulinemia on skin microcirculation in healthy volunteers. World J Diabetes (2013) 0.75
C-peptide has no effect on forearm blood flow during local hyperinsulinaemia in healthy humans. Br J Clin Pharmacol (2003) 0.75
White-coat hypertension as a cause of cardiovascular dysfunction. Lancet (1996) 4.68
Polymorphisms in angiotensin-converting-enzyme gene and progression of IgA nephropathy. Lancet (1995) 4.34
Effect of renal-artery stenting on progression of renovascular renal failure. Lancet (1997) 3.89
The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia (2010) 3.20
Trans-ethnic fine mapping of a quantitative trait locus for circulating angiotensin I-converting enzyme (ACE). Hum Mol Genet (2001) 2.75
Measured haplotype analysis of the angiotensin-I converting enzyme gene. Hum Mol Genet (1998) 2.53
Analysis of the pressor dose response. Clin Pharmacol Ther (1982) 2.44
Effects of prostaglandins, theophylline, and cholera exotoxin upon transmucosal water and electrolyte movement in the canine jejunum. Gastroenterology (1971) 2.39
Immediate cardiovascular responses to oral prazosin--effects of concurrent beta-blockers. Clin Pharmacol Ther (1981) 2.36
Do men develop type 2 diabetes at lower body mass indices than women? Diabetologia (2011) 2.12
Small bowel morphology in experimental canine cholera. A light and electron microscopic study. Lab Invest (1970) 2.12
A pharmacodynamic and pharmacokinetic assessment of a new alpha-adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects. Br J Clin Pharmacol (1982) 2.06
Nifedipine GITS. Lancet (1993) 1.94
Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab (2001) 1.89
Doxazosin, an alpha 1-adrenoceptor antagonist: pharmacokinetics and concentration-effect relationships in man. Br J Clin Pharmacol (1983) 1.89
Glucocorticoid receptor polymorphism, skin vasoconstriction, and other metabolic intermediate phenotypes in normal human subjects. J Clin Endocrinol Metab (1998) 1.80
Implementation of national diabetes retinal screening programme is associated with a lower proportion of patients referred to ophthalmology. Diabet Med (2005) 1.75
Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension (1999) 1.58
Aluminium toxicity during regular haemodialysis. Br Med J (1978) 1.54
Verapamil pharmacokinetics and apparent hepatic and renal blood flow. Br J Clin Pharmacol (1985) 1.46
Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci (Lond) (2000) 1.44
Imaging with pentavalent [99mTc]DMSA in patients with medullary cancer of the thyroid. J Nucl Med (1988) 1.41
Atrophy of villi with hypertrophy and hyperplasia of Paneth cells in isolated (thiry-Vella) ileal loops in rabbits. Light-microscopic studies. Gastroenterology (1975) 1.41
Kinetic and dynamic comparison of piretanide and furosemide. Clin Pharmacol Ther (1978) 1.40
Sexual precocity in a 4 year old boy. BMJ (2010) 1.39
Patient guidance after 131I therapy: time for change? Lancet (1992) 1.38
Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet (1992) 1.33
The role of laparoscopic adrenalectomy for adrenal tumours of 6 cm or greater. Surg Endosc (2007) 1.31
Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the risks? Diabetologia (2013) 1.26
Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. Proc Natl Acad Sci U S A (1992) 1.23
Plasmapheresis in the treatment of dialysis encephalopathy. Lancet (1978) 1.23
A pragmatic approach to the pressor dose-response as an index of vascular reactivity and adrenoceptor function in man. Br J Clin Pharmacol (1987) 1.22
Evidence for postjunctional vascular alpha 2-adrenoceptors in peripheral vascular regulation in man. Clin Sci (Lond) (1983) 1.22
How reproducible is bilateral forearm plethysmography? Br J Clin Pharmacol (1998) 1.21
The effect of nisoldipine on apparent liver blood flow and effective renal plasma flow. Br J Clin Pharmacol (1985) 1.20
Self-poisoning with sustained-release aminophylline: secondary rise in serum theophylline concentration after charcoal haemoperfusion. Br Med J (Clin Res Ed) (1982) 1.20
Bronchodilator effect of atrial natriuretic peptide in asthma. BMJ (1989) 1.20
The pressor dose-response in clinical cardiovascular pharmacology. Br J Clin Pharmacol (1987) 1.17
Preliminary experience with a hospital blood pressure follow up clinic with nurse practitioner assessment and microprocessor based data retrieval. Br Med J (Clin Res Ed) (1984) 1.16
Kinetic-dynamic relations and individual responses to enalapril. Hypertension (1990) 1.16
Dietary sodium restriction impairs insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab (1998) 1.14
Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. Circulation (1996) 1.11
Effect of age on the responsiveness of vascular alpha-adrenoceptors in man. J Cardiovasc Pharmacol (1982) 1.10
Expression of 11beta-hydroxylase and aldosterone synthase genes in the rat brain. J Mol Endocrinol (2000) 1.09
Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia (2012) 1.08
Apparent cortisone reductase deficiency: a functional defect in 11beta-hydroxysteroid dehydrogenase type 1. J Clin Endocrinol Metab (1999) 1.06
Nifedipine: individual responses and concentration-effect relationships. Hypertension (1988) 1.03
Hypercholesterolaemia in treated hypertensives: a controlled trial of intensive dietary advice. J Hypertens Suppl (1989) 1.03
Mistyping of the human angiotensin-converting enzyme gene polymorphism: frequency, causes and possible methods to avoid errors in typing. J Mol Endocrinol (1996) 1.03
The pharmacodynamics and dose-response relationships of the angiotensin converting enzyme inhibitor, cilazapril, in essential hypertension. Br J Clin Pharmacol (1986) 1.03
Effects of UK 69 578: a novel atriopeptidase inhibitor. Lancet (1989) 1.03
Experimental central nervous system phaeohyphomycosis following intranasal inoculation of Xylohypha bantiana in cortisone-treated mice. Mycopathologia (1987) 1.02
Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme. Hypertension (1995) 1.01
Vascular and aldosterone responses to angiotensin II in normal humans: effects of nicardipine. J Cardiovasc Pharmacol (1986) 1.00
Influence of elevated plasma levels of atrial natriuretic factor on bronchial reactivity in asthma. Am Rev Respir Dis (1991) 0.99
Peroxidase activity in relation to iodide, 17 beta-oestradiol and thioureylene drug uptake in human polymorphoneutrophils. Biochem Pharmacol (1984) 0.98
Familial pattern of corticosteroids and their metabolism in adult human subjects--the Scottish Adult Twin Study. J Clin Endocrinol Metab (1999) 0.98
5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) inhibits insulin-stimulated glucose transport in 3T3-L1 adipocytes. Diabetes (2000) 0.98
Population pharmacokinetics of gentamicin in patients with cancer. Br J Clin Pharmacol (1998) 0.98
A genome-wide screen in 1119 relative pairs with autoimmune thyroid disease. J Clin Endocrinol Metab (2005) 0.98
The determination of labetalol in plasma by high-performance liquid chromatography using fluorescence detection. J Pharmacol Methods (1981) 0.97
The atherogenic lipoprotein phenotype and vascular endothelial dysfunction. Atherosclerosis (1998) 0.96
ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans. Circulation (1998) 0.96
Seizures after infusion of factor VIII. Br Med J (Clin Res Ed) (1983) 0.95
Microemulsions for oral delivery of insulin: design, development and evaluation in streptozotocin induced diabetic rats. Eur J Pharm Biopharm (2010) 0.95
Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2. Hypertension (1999) 0.95
The pharmacokinetics and angiotensin converting enzyme inhibition dynamics of cilazapril in essential hypertension. Br J Clin Pharmacol (1989) 0.94
Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens (1992) 0.94
Cd36 and molecular mechanisms of insulin resistance in the stroke-prone spontaneously hypertensive rat. Diabetes (2000) 0.94
Pregnancy complicated by Cushing's syndrome: potential hazard of metyrapone therapy. Case report. Br J Obstet Gynaecol (1985) 0.94
Fetal angiotensin II levels and vascular (type I) angiotensin receptors in pregnancies complicated by intrauterine growth retardation. Br J Obstet Gynaecol (1993) 0.93
Disopyramide in renal impairment. Lancet (1978) 0.92
Insulin as a vascular hormone: implications for the pathophysiology of cardiovascular disease. Clin Exp Pharmacol Physiol (1998) 0.92
Clinical evaluation of endralazine (BO22708), a new vasodilator, in essential hypertension. Clin Exp Hypertens A (1982) 0.92
Intestinal involvement in Waldenstrom's macroglobulinemia. Gastroenterology (1973) 0.92
AMP-activated protein kinase is activated in adipose tissue of individuals with type 2 diabetes treated with metformin: a randomised glycaemia-controlled crossover study. Diabetologia (2011) 0.92
Exercise training has greater effects on insulin sensitivity in daughters of patients with type 2 diabetes than in women with no family history of diabetes. Diabetologia (2008) 0.92
Prediction of the antihypertensive response to enalapril. J Hypertens (1990) 0.92
Area-based socioeconomic status, type 2 diabetes and cardiovascular mortality in Scotland. Diabetologia (2012) 0.91
Intravascular coagulation induced by guinine. Unexpected hazard of 'bitter lemon'. Scott Med J (1979) 0.91
The effect of estradiol and a combined estradiol/progestagen preparation on insulin sensitivity in healthy postmenopausal women. J Clin Endocrinol Metab (1999) 0.90
Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics. Br J Clin Pharmacol (1987) 0.90
Insulin-mediated vasodilation and glucose uptake are functionally linked in humans. Hypertension (1999) 0.90
Renal lead excretion. Br Med J (1977) 0.89
Chronic low-dose infusions of dexamethasone in rats: effects on blood pressure, body weight and plasma atrial natriuretic peptide. J Hypertens (1988) 0.89
The pharmacokinetics of endralazine in essential hypertensives and in normotensive subjects. Br J Clin Pharmacol (1983) 0.89
Dexamethasone-suppressible hyperaldosteronism. Adrenal transition cell hyperplasia? Hypertension (1986) 0.89